FN1 and breast carcinoma: Exogenous FN1 confers Tamoxifen resistance in breast cancer through interaction with β1 integrin and modulates the activity of estrogen receptor [198] and nanoformulation, that simultaneously targets ER and FN1/β1 integrin interactions, has been proposed as potential therapeutic strategy for the management of breast tumors [199].